Interpretation of key points from the White Paper on Helicobacter pylori Infection Prevention and Control in China
-
摘要: 《中国幽门螺杆菌感染防控》白皮书在2023年6月3日正式公布，对我国的幽门螺杆菌(Helicobacter pylori，HP)研究及其防治工作产生了显著影响。白皮书面向行政管理者、医药卫生专业人员和广大民众群体3个层面的需求，从HP的病原学介绍、感染流行病学特征、疾病负担、诊治现状、防控策略等多个方面进行了系统阐述。特别是对其病原学及感染特征的认识和理解、中国人群HP感染的疾病负担分析可作为国家防控策略制订和相关公共卫生资源投入的重要依据。白皮书还详尽介绍了HP感染的诊断方法及耐药性检测技术，并讨论了制定根除方案时需考虑的多个因素。它还指出HP感染干预是预防胃癌的关键措施，强调了中医药在防控中的作用，以及全社会对HP感染有效防控的必要性。本文拟对白皮书的关键内容进行初步解读，旨在帮助读者更深入理解相关信息，并促进HP感染的防控工作。Abstract: The White Paper on Helicobacter pylori Infection Prevention and Control in China was officially released on June 3, 2023, significantly impacting research and control measures against Helicobacter pylori(H.pylori) in China. Targeting administrators, healthcare professionals, and the general public, the white paper comprehensively discusses various aspects including the etiology of H.pylori, epidemiological characteristics of the infection, disease burden, current diagnostic and treatment status, and prevention strategies. Notably, its insights into the pathogenesis and infection traits, along with an analysis of the disease burden of H.pylori infections among the Chinese population, serve as crucial foundations for formulating national prevention strategies and allocating public health resources. Additionally, the document extensively covers diagnostic methods and antimicrobial resistance testing techniques for H.pylori infections and discusses multiple factors to consider when developing eradication protocols. It also highlights H.pylori infection intervention as a primary measure for gastric cancer prevention, underscores the significance of Traditional Chinese Medicine in infection control, and stresses the necessity of societal participation in effective infection prevention and control. This article aims to provide a preliminary interpretation of the white paper's key contents, intending to deepen readers' understanding of the information and promote H.pylori infection prevention and control efforts.
-
Key words:
- Helicobacter pylori /
- infection /
- prevention and control /
- white paper /
- key points /
- interpretation
-
-
[1] 中国疾病预防控制中心传染病预防控制所. 中国幽门螺杆菌感染防控白皮书[EB/OL]. [2023-06-03].
https://icdc.chinacdc.cn/zxxx/gzdt/202306/t20230603_266504.html .[2] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. doi: 10.3322/caac.21763
[3] 胡伏莲, 张声生. 全国中西医整合治疗幽门螺杆菌相关"病-证"共识[J]. 胃肠病学和肝病学杂志, 2018, 27(9): 1008-1016. doi: 10.3969/j.issn.1006-5709.2018.09.012
[4] 王萍, 卞立群, 杨倩, 等. 慢性胃炎中医诊疗专家共识(2023)[J]. 中华中医药杂志, 2023, 38(12): 5904-5911. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202312106.htm
[5] 丁松泽, 杜奕奇, 陆红, 等. 中国居民家庭幽门螺杆菌感染的防控和管理专家共识(2021年)[J]. 胃肠病学, 2022, 27(12): 734-746.
[6] 中华医学会儿科学分会消化学组, 国家儿童医学中心消化专科联盟, 中华儿科杂志编辑委员会. 中国儿童幽门螺杆菌感染诊治专家共识(2022)[J]. 中华儿科杂志, 2023, 61(7): 580-587.
[7] 刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.
[8] Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht Ⅳ/Florence consensus report[J]. Gut, 2022, gutjnl-2022-327745.
[9] 张学智, 魏玮, 蓝宇. 成人幽门螺杆菌引起的胃炎中西医协作诊疗专家共识(2020, 北京)[J]. 中医杂志, 2020, 61(22): 2016-2024.
[10] 张思琪, 游运舸. 基于中医传承辅助平台分析中药治疗幽门螺杆菌相关性胃炎用药规律及配伍特点[J]. 中国现代医生, 2022, 60(8): 118-122, 封3.
[11] 张泰, 张北华, 马祥雪, 等. 从伏邪学说辨析幽门螺杆菌阳性慢性萎缩性胃炎炎-癌转化病机[J]. 中华中医药杂志, 2022, 37(6): 3132-3136. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY202206034.htm
[12] 王秋明, 胡晶, 杨雪, 等. 144例低超基准值幽门螺杆菌感染患者临床特点及中医辨证治疗[J]. 实用临床医药杂志, 2021, 25(18): 66-70. https://www.cnki.com.cn/Article/CJFDTOTAL-XYZL202118015.htm
-
计量
- 文章访问数: 458
- PDF下载数: 156
- 施引文献: 0
下载: